Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug
09:01am, Friday, 15'th Sep 2023
Iovance (IOVA) rises despite the FDA's postponement of the decision date regarding the regulatory filing for its lead candidate, lifileucel, to treat advanced melanoma due to resource constraints.
Iovance Biotherapeutics stock soars, recovering on positive engagement with FDA
08:27am, Friday, 15'th Sep 2023
Iovance Biotherapeutics (NASDAQ:IOVA) stock looked to soar at Friday's market open, recovering from a steep loss on Thursday after the company said the US Foood and Drug Administration (FDA) needed mo
Why Shares of Iovance Biotherapeutics Dropped Thursday
04:36pm, Thursday, 14'th Sep 2023
One analyst downgraded his price target for the stock on Wednesday. Iovance's lead therapy is Lifileucel, which treats multiple cancer types.
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
07:31am, Thursday, 07'th Sep 2023
SAN CARLOS, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in
Iovance: November PDUFA, But A History Of Delays And Underwhelming Data
04:01pm, Wednesday, 30'th Aug 2023
Iovance Biotherapeutics, Inc. has a deep pipeline of cancer immunotherapies, but has faced delays and issues with duration of response. The company's lead asset, lifileucel, is being tested in multipl
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
11:53pm, Monday, 28'th Aug 2023
Investing in biotech stocks is challenging even when you're investing in established companies with commercially available drugs and expansive pipelines. And investing in up-and-coming biotech stocks
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2
12:57pm, Wednesday, 09'th Aug 2023
Iovance (IOVA) reports mixed second-quarter results as earnings beat estimates but sales miss the mark.
Oral Presentation of Cohort 3A Data from IOV-COM-202 Phase 2 Clinical Trial of LN-145 in Combination with Pembrolizumab in Anti-PD1-naïve Advanced (metastatic or unresectable) Non-Small Cell Lung Can
Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug
12:32pm, Tuesday, 11'th Jul 2023
Based on feedback from the FDA, Iovance's (IOVA) ongoing mid-stage study on LN-145 in NSCLC could support approval under the accelerated pathway. IOVA also reports encouraging preliminary data.
Why Iovance Biotherapeutics Stock Is Dropping Tuesday
11:18am, Tuesday, 11'th Jul 2023
Iovance is close to launching its first in-house developed therapy. The company recently purchased cancer drug Proleukin from Clinigen Limited.
Why Is Iovance Biotherapeutics (IOVA) Stock Down 10% Today?
09:40am, Tuesday, 11'th Jul 2023
Iovance Biotherapeutics (NASDAQ: IOVA ) stock is sliding lower on Tuesday after the company announced details of a public share offering. According to a press release, Iovance Biotherapeutics is selli
Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning
09:26am, Tuesday, 11'th Jul 2023
Futures on the Nasdaq inched higher Tuesday morning. Viridian fell despite announcing some favorable early results from a clinical trial.
WD-40 shares climb after earnings top estimates, Iovance stock slumps on offering, and other stocks on the move
05:17am, Tuesday, 11'th Jul 2023
WD-40 Co. shares WDFC, +2.08% rallied 4% in premarket trade after the company topped Wall Street estimates for the quarter.
Biotech Stock Pops on Reaction to Experimental Therapy
10:22am, Monday, 10'th Jul 2023
Iovance Biotherapeutics Inc (NASDAQ:IOVA) was last seen up 2.4% at $7.42, after the U.S. Food and Drug Administration (FDA) said a late-stage study of its experimental lung cancer therapy , LN-145 TI
Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study
10:05am, Friday, 16'th Jun 2023
Iovance (IOVA) announces randomizing the first patient in the TILVANCE-301 study evaluating the safety and efficacy of its lifileucel/Keytruda combo therapy in frontline advanced melanoma patients.
